Equities

Bristol-Myers Squibb Co

0R1F:LSE

Bristol-Myers Squibb Co

  • Price (USD)60.60
  • Today's Change2.20 / 3.77%
  • Shares traded12.72k
  • 1 Year change5.36%
  • Beta0.2814
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.

  • Revenue in USD (TTM)48.19bn
  • Net income in USD7.05bn
  • Incorporated1933
  • Employees34.10k
  • Location
    Bristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
  • Phone+1 (302) 658-7581Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		0R1F:LSE since
announced		Transaction
value
Orbital Therapeutics IncAnnounced10 Oct 202510 Oct 2025Announced35.63%1.50bn
2Seventy Bio IncDeal completed10 Mar 202510 Mar 2025Deal completed-0.80%238.66m
Data delayed at least 20 minutes, as of Feb 06 2026 19:14 GMT.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.